MITOTOX

Drug

D0821 | bryostatin 1

Toxicity	Dose	Species	Model	Method	Action	Positive criterion	Reference
MEMBRANE POTENTIAL	0.01±0.01	human	qHTS-HepG2	MMP assay	decrease	IC50	163
MEMBRANE POTENTIAL	0.001	human	HepG2	MMP assay	decrease	IC50	163
MEMBRANE POTENTIAL	0.79±1.07	rat	hepatocytes	MMP assay	decrease	IC50	163

(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1(3,7).1(11,15)]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate;	(1S-(1R,3R,5Z,7S,8E,11R,12R(2E,4E),13E,15R,17S(S),21S,23S,25R*))-25-(Acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl 2,4-octadienoate	2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-((1R)-1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (2E,4E)-
2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo(21.3.1.13,7.111,15)nonacos-8-en-12-yl ester, (1S-(1R,3R,5Z,7S,8E,11R,12R(2E,4E),13E,15R,17S(S),21S,23S,25R*))-	37O2X55Y9E	83314-01-6
BDBM50258529	BMY-45618	BRN 4349157
BRYOSTATIN	Bryostatin 1	Bryostatin 1, >=99%, solid
Bryostatin-1	CAS-83314-01-6	CHEBI:88353
CHEMBL449158	DSSTox_CID_26876	DSSTox_GSID_46876
DSSTox_RID_81981	DTXSID8046876	MFCD00893832
MJQUEDHRCUIRLF-TVIXENOKSA-N	NCGC00181150-01	NSC 339555
NSC-339555	Q27095907	SCHEMBL182960
Tox21_112754	UNII-37O2X55Y9E	ZINC169357315